Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 196 от 240

Предстои набиране

Establishment of Biomarker Panel For Forecasting Chronic Graft-Versus-Host Disease (cGVHD) After Allo-HSCT

Chronic Graft-Versus-Host Disease

This study is a single-center observational clinical study. Participants were enrolled as two cohorts of patients including discovery cohort and validation cohort. A total of consecutive 1000 patients receiving allo-HSCT in our center from 2021.01 to 2023.06 were retrospectively included as discovery cohort. A total of consecutive 500 recipients from 2023.06 to 2024.06 were retrospectively enrolled as validation cohort. Heparinized blood samples were collected prospectively at day +90 after HSCT and the onset of manifestations in patients with cGVHD or at matched time points in controls. Patients in the validation cohort also had samples drawn at approximately day +90. We used multiplex mass spectrometry with pooled plasma for biomarker discovery in comparing proteomic profiles between patients with and without chronic GVHD.

Начало: 01.04.2026 Край: 01.12.2028 Възраст: от 18 г.

Institute of Hematology & Blood Diseases Hospital, Chin NCT07539220

Предстои набиране

Does Pre-operative Gastric Ultrasound Influence Anaesthetic Decision-Making in Chronic Pain Patients? A Prospective Observational Cohort.

Gastric Ultrasound Gastric Ultrasound in Chronic Opioid Use (≥2 Weeks) Gastric Ultrasound in Poorly Controlled Acute-on-chronic Pain Gastric Ultrasound in Acute Opioid Administration Within 24 Hours Prior to the Procedure +3

Gastric POCUS has been validated and shown to be an accurate diagnostic tool in both healthy individuals and medically complex patient populations. Regional anaesthesiologists and pain management physicians frequently provide sedation or anaesthetic care for medically complex patients who fall outside the limited applicability of existing fasting guidelines, including patients with chronic pain, poor acute-on-chronic pain control, and those receiving acute or chronic opioid therapy. These patients are at risk of delayed gastric emptying and may therefore benefit from additional pre-procedural assessment using gastric ultrasound prior to elective interventions

Начало: 01.04.2026 Край: 01.08.2027 Възраст: от 18 г.

United Arab Emirates Danat Al Emarat Hospital NCT07537582

Предстои набиране Фаза 3

Normal Saline Infusion After Intravenous Thrombolysis in Stroke

Brain Infarction

The intravenous administration of abundant normal saline is an easy-to-use strategy commonly employed to expand the blood volume. This study aimed to evaluate the efficacy and safety of the early administration of an abundant normal saline infusion after intravenous thrombolysis for promoting functional independence in patients with acute ischemic stroke. This multicenter, randomized, phase III clinical trial intends to enroll stroke participants who have undergone intravenous thrombolysis. Eligible patients are randomized to receive either abundant intravenous normal saline infusion (2,000-2,500 mL; normal saline group) or a small volume of intravenous normal saline infusion (≤600 mL; control group) immediately after thrombolysis. The primary outcome is the comparison of the ordinal modified Rankin Scale score at 90 days (±3) after randomization between the treatment groups.

Начало: 01.04.2026 Край: 01.09.2029 Възраст: 18–80 г.

China Tianjin Medical University General Hospital NCT07497542

Предстои набиране

SEHAT Virtual Oral Health Promotion for School Adolescents in Pakistan

Oral Health Behavior Change

The goal of this cluster-randomized trial is to learn if the SEHAT program works to improve oral health among school adolescents in Pakistan. It will also assess how the program affects oral health behaviors and knowledge. The main questions it aims to answer are: 1. Does the SEHAT program improve toothbrushing behavior and oral hygiene? 2. Does the SEHAT program reduce plaque and gingival scores among adolescents? 3. Does the program improve oral health knowledge and awareness? Researchers will compare the SEHAT virtual intervention with conventional oral health education and a control group to see which approach is most effective. Participants will: 1. Take part in either the virtual SEHAT session or conventional in-person oral health education, or receive no intervention (control) 2. Watch structured 30-minute sessions delivered via Zoom (virtual group) or classroom instruction (conventional group) 3. Participate in follow-up assessments to measure plaque, gingival indices, and oral health knowledge and behaviors.

Начало: 01.04.2026 Край: 01.09.2027 Възраст: 11–15 г.

Pakistan Shifa College of Dentistry NCT07536958

Предстои набиране

Assessment of Climate Change Related Heat Stress Among Workers in Upper Egypt : Impact of Intervention Program on Physiological Responses

Climate Change Heat Stress

Climate change has a significant impact on human health and productivity at work. According to the Intergovernmental Panel on Climate Change (IPCC) and the United Nations, climate change is one of the most significant global challenges of the 21st century. It is defined by the United Nations Framework Convention on Climate Change (UNFCCC) as "a change in climate that is directly or indirectly attributable to human activity that alters the composition of the global atmosphere and that is in addition to the natural climate variability observed over comparable time periods". Climate change has led to a significant increase in global average temperatures; temperatures on average have increased by about 1.1°C since pre-industrial times . In addition, the intensity, frequency, and duration of heatwaves have been rapidly increasing around the globe . Nineteen out of the 20 warmest years on record have occurred since 2000. Occupational exposure associated with rising temperatures and climate change has become a concern to the health and safety, productivity, and social well-being of the world's diversified workforce. As a result, the 2030 Sustainable Development Goals (SDGs) are focused on ensuring healthy lifestyles, promoting wellbeing, ensuring decent employment and work capacity, and combating the effects of climate change on all sectors of development. Climate change continues to pose an immediate and long-term threat to human survival around the world; hence, the global agenda to promote humanity's well-being by combating rising temperatures and the impacts of climate change, as stated in the Sustainable Development Goals (SDG 13). In tropical regions in low-and middle-income countries, rural populations often work in hot climates, live in dwellings that are not thermally efficient, and are unable to access fans or air conditioners. Laboring in high heat increases the risk of heat-related injuries and illnesses. Egypt is especially vulnerable to climate change due to its geographic location and reliance on climate sensitive economic sectors. Exposure to heat can cause a range of adverse health effects including damage to major organs and even death if the core temperature of the body exceeds 42 °C . Working people's exposure to hot environments to heat-related health effects such respiratory, heart, and renal illnesses. Even in healthy people, heat stress has the potential to produce acute kidney damage through volume depletion. Numerous heat-related symptoms, including exhaustion, headaches, muscle cramps, weakness, nausea, vomiting, tachycardia, hyperventilation, and chest pain that may be mild or severe depending on severity, ataxia, hypotension, syncope, and momentary changes in mental status, can all be signs of heat stress. It is possible that in some cases the asymptomatic rise in serum creatinine levels represents a dehydration-related decrease in renal perfusion without structural injury or that the rise in the creatinine level does not represent a true fall in the estimated glomerular filtration rate (eGFR). However, there is concern that changes in the creatinine level during the work shift may represent injury to the kidneys, which, if repetitive, could confer a predisposition to chronic kidney disease

Начало: 01.04.2026 Край: 01.09.2027 Възраст: 18–60 г.

Assiut University NCT07538778

Предстои набиране

PREcision MEDicine In Achalasia (PREMEDIA) - Cohort

Type III Achalasia EGJ Outflow Obstruction With Spastic/Hypercontractile Features Jackhammer Esophagus Distal Esophageal Spasm

The goal of this observational study is to learn about how the doctor decides how long to cut t the esophageal muscle during Per-Oral Endoscopic Myotomy (POEM) in patients with difficulty swallowing due to certain conditions. The main question it aims to answer is: does pre-POEM testing help the physician choose how long to cut the muscle. Participants will allow researchers to access their standard of care information in their medical record, complete questionnaires at up to 6 times over a 2-year period.

Начало: 01.04.2026 Край: 01.03.2030 Възраст: от 18 г.

United States Northwestern University NCT07293689

Предстои набиране Фаза 3

Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis

Hemophagocytic Lymphohistiocytosis

Hemophagocytic lymphohistiocytosis (HLH) is an immune-mediated disorder characterized by hyperactivation of the immune system, leading to a cytokine storm responsible for organ failures. Consequently, patients with HLH often require intensive care management, where their short-term prognosis is compromised (1-month mortality: 30 to 40%). Therapeutic management is urgent and consists in treating associated pathologies and employing immunomodulatory therapy. Currently, there are no clear and consistent recommendations for guiding immunomodulatory treatment in HLH due to the lack of high-level evidence studies. Experts recommend corticosteroid therapy for mild forms, whereas etoposide is proposed for severe cases, especially those with organ failures. However, in clinical practice, its use in patients with multi-organ failure is not systematic due to concerns about potential severe side effects and uncertainty regarding the contribution of severe sepsis to the clinical and biological presentation. Consequently, initiation of etoposide is sometimes delayed. Our hypothesis is that early treatment of severe HLH associated with organ failure using etoposide could reduce organ failures associated with this syndrome. Therefore, we aim to compare two strategies for initiating etoposide in severe HLH in intensive care: an early strategy where etoposide is prescribed at the onset of HLH-related organ failure, and a delayed strategy where etoposide is prescribed only if there is unfavorable progression (or lack of improvement) after treating associated pathologies, associated with corticosteroid therapy.

Начало: 01.04.2026 Край: 01.02.2030 Възраст: от 18 г.

France Assistance Publique - Hôpitaux de Paris NCT07497438

Предстои набиране Фаза 1

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

Colorectal Cancer Gastric Adenocarcinoma Esophageal Adenocarcinoma Gastroesophageal Adenocarcinoma

This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor \[CAR\] T), in adult participants with advanced gastrointestinal (GI) cancers. The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). Part 1 of the study will evaluate the safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion (RDE); Part 2 will evaluate the safety and efficacy of DISP-10 in participants treated at the RDE.

Начало: 01.04.2026 Край: 01.04.2046 Възраст: от 18 г.

United States Dispatch Biotherapeutics NCT07544589

Предстои набиране Фаза 4

Use Dexmedetomidine To Protect Myocardial Injury Evaluation

Coronary Heart Disease Myocardial Injury Myocardial Infarction Dexmedetomidine

The goal of this clinical trial is to learn if preoperative intranasal dexmedetomidine works to reduce perioperative myocardial injury and myocardial infarction in patients undergoing elective percutaneous coronary intervention (PCI). It will also learn about the safety of intranasal dexmedetomidine. The main questions it aims to answer are: Does preoperative intranasal dexmedetomidine lower the incidence of perioperative myocardial injury and myocardial infarction after PCI? Does intranasal dexmedetomidine cause safety concerns in patients undergoing PCI? Researchers will compare intranasal dexmedetomidine to a placebo (a look-alike substance that contains no drug) to see if intranasal dexmedetomidine works to protect the heart during PCI. Participants will: Receive either intranasal dexmedetomidine (100 μg) or a placebo (normal saline) 15 minutes before the PCI procedure Undergo blood tests to measure cardiac troponin levels before and after the procedure Be followed for up to 30 days after the procedure to record any heart-related events or side effects

Начало: 01.04.2026 Край: 01.04.2028 Възраст: 18–85 г.

China Second Affiliated Hospital, School of Medicine, Zhejian NCT07549282

Предстои набиране

Efficacy of Dry Needling for Releasing the Sacrotuberous Ligament in Patients With Sacroiliac Joint Dysfunctions

Sacroiliac Joint Dysfunction

Sacroiliac joint dysfunction is a common source of low back and pelvic pain, often caused by improper load transfer through the pelvis. The sacrotuberous ligament stabilises the sacroiliac joint by limiting sacral nutation and supporting posterior pelvic structures. The sacroiliac joint connects the sacrum to the ischial tuberosity and integrates with muscles like the gluteus maximus and biceps femoris. Tightness, dysfunction, or pain in the sacrotuberous ligament can exacerbate sacroiliac joint dysfunction by altering mechanics. Dry needling is increasingly used for myofascial pain and muscle dysfunction. Applying dry needling to release ligamentous structures is novel and may improve the biomechanics of the sacroiliac joint by alleviating tension in the sacrotuberous ligament. The aim of the study is to investigate the efficacy of dry needling for releasing the sacrotuberous ligament in patients with sacroiliac joint dysfunctions on pain intensity, functional disability, and biomechanical changes, along with routine physical therapy compared to sham dry needling and routine physical therapy.

Начало: 01.04.2026 Край: 01.11.2026 Възраст: 40–65 г.

Pakistan University of Social Welfare and Rehabilitation Science NCT07550933

Предстои набиране

Sebum Metabolomics and Lipidomics for Clinical Applications

Acne Atopic Dermatitis Seborrheic Dermatitis Psoriasis +1

This study aims to develop a standardized workflow for sebum sampling and metabolomics/lipidomics analysis using Sebutape. A total of 200 participants will be recruited, including healthy individuals, patients with skin diseases, individuals undergoing dermatological treatments or using skincare products, and a subset of healthy participants receiving short-term topical antibiotic intervention. The study will investigate sebum composition, skin microbiome profiles, and their interactions under different conditions to explore potential biomarkers and clinical applications.

Начало: 01.04.2026 Край: 31.03.2029 Възраст: от 20 г.

National Taiwan University Hospital NCT07549828

Предстои набиране Фаза 2/3

Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

GIST - Gastrointestinal Stromal Tumor Advanced

NB003-04 is a phase II/III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profile of NB003 in patients with gastrointestinal stromal tumors aged 18 years and above (or the legal adult age of consent per local regulations, whichever is older). Participants who are eligible for this study are those who have experienced disease progression or documented intolerance following treatment with either imatinib and sunitinib or following treatment with imatinib. This study consists of two parts. Part 1 (hereinafter referred to as Part 1) compares the efficacy of NB003 versus regorafenib in patients who need a third-line therapy for GIST who have failed sequential therapy with imatinib and sunitinib. Part 2 (hereinafter referred to as Part 2) evaluates the efficacy of NB003 in patients who need a second-line therapy for GIST who have failed treatment with imatinib.

Начало: 01.04.2026 Край: 01.09.2028 Възраст: от 18 г.

China, South Korea Ningbo Newbay Technology Development Co., Ltd NCT07379047

Предстои набиране

Evaluating the Feasibility of Prehospital Lung Ultrasound

Congestive Heart Failure(CHF) Pulmonary Edema

The goal of this prospective nonrandomized study is to determine if a lung ultrasound exam improves diagnosis of respiratory distress in patients being treated by Emergency Medical Services. The main question it aims to answer is whether ultrasound use increases likelihood of correctly diagnosing heart failure. Additional questions include: * How well can paramedics obtain and interpret ultrasound images? * How does ultrasound use change treatment received by patients? * How does ultrasound use impact patient outcomes? Participants will receive a lung ultrasound exam, but otherwise receive standard evaluation and care. Patients who receive ultrasound will be compared to those who did not receive ultrasound for logistical reasons and patients from before the use of ultrasound. Ultrasound will not be withheld from any patient for the purposes of the study.

Начало: 01.04.2026 Край: 01.04.2028 Възраст: от 18 г.

United States Rutgers, The State University of New Jersey NCT07549334

Предстои набиране

Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma

Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy Upper Tract Urothelial Carcinoma

UTUC is a cancer that develops in the lining of the kidney or ureter. The standard treatment is radical nephroureterectomy, which removes the kidney and ureter. Although this surgery can control the cancer, it permanently reduces kidney function. Endoscopic treatment can serve as a kidney-sparing approach for low-risk UTUC; however, in high-risk patients, the high rate of upper tract local recurrence after endoscopic treatment remains the primary failure pattern. This study aims to evaluate the efficacy and safety of radiotherapy-involved kidney-sparing treatment for UTUC. The main questions this study aims to answer are: Can this multimodal kidney-sparing strategy reduce local recurrence of UTUC compared with endoscopic treatment alone? Participants in the kidney-sparing group will: Undergo endoscopic surgery to remove the tumor; Receive systemic therapy with disitamab vedotin and toripalimab; Receive targeted radiotherapy after surgery. Participants will undergo regular follow-up visits, including imaging examinations and endoscopic evaluations, to monitor for recurrence or disease progression. The results of this study may help determine whether a multimodal kidney-sparing treatment strategy could become a safe and effective option for selected patients with high-risk UTUC.

Начало: 01.04.2026 Край: 01.04.2030 Възраст: от 18 г.

China Peking University First Hospital NCT07504939

Предстои набиране Фаза 4

Prophylaxis of Recurrent Erysipelas in Lower Limbs: compreSsion thErapy vs aNTibiotics and Compression Therapy.

Recurrent Erysipelas

Erysipelas (superficial cellulitis) is a frequent streptococcal bacterial infection. Each episode of erysipelas may worsen preexisting lymphedema and evolve to life-threatening necrotizing soft-tissue infection. Moreover, each attack of cellulitis may worsen lymphatic damage and therefore favour additional attacks. Recurrence is frequent: 10-30% of cases and even up to 50%. In this context, at least 2 episodes of erysipelas in the same limb during a 1-year period defines recurrent erysipelas requiring prophylaxis. Such prophylaxis is based usually on penicillin therapy. Compression was evaluated only in a monocentric randomized controlled trial, and was never compared to antibioprophylaxis. The investigators hypothesized that compression therapy alone might represent a single intervention for prophylaxis of erysipelas recurrence as efficient as long-term antibiotic prophylaxis with compression therapy combined. This study is a multicenter, parallel groups, assessor-blinded, non-inferiority, randomized clinical trial. Main objective is to evaluate whether supervised compression therapy alone is non-inferior to supervised compression therapy + oral penicillin in controlling relapse of recurrent erysipelas. Secondary objectives are to assess time to first recurrence ; to assess the severity of the recurrence ; to assess the safety of the intervention to assess the quality of life during the prophylaxis phase ; to assess the adherence of patients with the intervention and to assess, in a joint analysis, that supervised compression therapy is both not inferior in terms of QALY and not more expensive at 1 year than supervised compression therapy + antibiotic. The study will included male or female adults who have had at least 2 episodes of recurrent erysipelas at the same leg within the previous 52 weeks, and no more than five episodes of erysipelas in the same areas of the lower limbs during the year before randomization. Experimental group is supervised compression therapy + emollient cream during 12 months and control group is supervised compression therapy + emollient cream + oral penicillin (phénoxyméthylpénicilline) during 12 months Main outcome is the proportion of patients with at least one recurrence of erysipelas during the 1-year prophylaxis phase, performed by an assessor-blinded. Patients will be identified in a hospital setting, or referred by physicians servicing the local region, or by direct advertising through patients' associations. If the patient gives consent to participate, at the end of a inclusion visit (V0), the randomization will be performed via the e-CRF. Prescriptions will then be issued on inclusion. Control group who will start antibiotic treatment at inclusion. A run-in period of 7 ±2 days will be planned between V0 and the beginning of the compression therapy for the both group, in order to get the prescribed elastic stockings, and to train the nurse in charge of the compression supervision. A nurse trained in the study will supervise the first applications of the compression in the patient's home. After inclusion visit (V0), a home visit by the liberal IDE will be planned at M1 for to check daily adherence (use of ATB or/and wearing compression and application of emollients). A patient diary must be completed from inclusion and during the follow-up period. Two telemedicine clinic were scheduled at M3 and M9 and two study visits were scheduled at M6 and M12 with a complete physical examination. All the evaluations will be performed by a blinded evaluator investigator. Supplementary telemedicine clinic(s) in case of potential recurrence of erysipelas will be done by the blinded evaluator in the presence of the nurse who will be at bedside of patient. The organization and design of the study will be realistic, and thus is designed to facilitate its feasibility and generalizability of results. In case of demonstration of non-inferiority of supervised compression therapy, patients with recurrent erysipelas will be spared of antibiotics first-line, and therefore suppress the impact of both long-term antibiotics on gut microbiota individuals and health burden of antibiotics at the population level.

Начало: 01.04.2026 Край: 01.04.2030 Възраст: от 18 г.

France University Hospital, Tours NCT07549594

Предстои набиране

Evaluating the Effects of an Electrical Stimulator on Improving the Walking Ability of Children With Cerebral Palsy

Cerebral Palsy Children Healthy Adults

The goal of this study is to see if gentle electrical stimulation can help children with cerebral palsy (CP) walk more easily. This stimulation, called neuromuscular electrical stimulation (NMES), sends small pulses to muscles to help them activate. Researchers will test different ways of using NMES to find out which method works best. Participants will walk on a treadmill at a comfortable speed while NMES is applied to leg muscles. The study will compare different stimulation settings to see which one helps the most.

Начало: 01.04.2026 Край: 01.07.2029 Възраст: 7–40 г.

United States University of Nebraska NCT06811545

Предстои набиране

DuoCor 2 DOMINATE Study

Advanced Heart Failure

Advanced heart failure is a life-threatening condition characterized by the inability of one or both ventricles to maintain adequate blood circulation. In such cases, medical treatments often prove ineffective, necessitating advanced treatment. Heart transplantation is the standard treatment for these patients, but it is severely limited by the shortage of donor hearts. As a result, mechanical circulatory support (MCS) devices are often employed. However, the most common form, the left ventricular assist device (LVAD), is only suitable for patients with isolated left ventricular dysfunction. This leaves a significant treatment gap for patients with biventricular failure. For this population, current options, such as total artificial hearts (TAHs) and biventricular assist devices (BiVADs), are associated with significant challenges, including high rates of adverse events and suboptimal long-term outcomes. The DuoCor Ventricular Assist System (VAS) is a next-generation MCS device specifically developed to address this need by providing simultaneous biventricular support. It incorporates two compact, good hemocompatible blood pumps designed for implantation in both the left and right heart, controlled via a single driveline and external controller. It aims to reduce surgical complexity, improve patient mobility, and minimize complications such as thrombosis and infection. The primary objective of this study is to evaluate the safety and efficacy of the DuoCor VAS as a treatment for advanced biventricular heart failure.

Начало: 01.04.2026 Край: 01.04.2029 Възраст: 18–75 г.

Germany Shenzhen Core Medical Technology CO.,LTD. NCT07233876

Предстои набиране

A Study to Understand the Accuracy of a New Breathing Device Compared to Standard Testing for Asthma and COPD

Asthma (Diagnosis) COPD (Chronic Obstructive Pulmonary Disease)

The diagnosis of either asthma or chronic obstructive pulmonary disease (COPD) is currently based on a combination of symptoms, different lung tests and sometimes a 'trial by treatment'. Both COPD and Asthma tests currently include forced breathing using a test known as spirometry which can be difficult and uncomfortable for people to perform and needs expert interpretation. Asthma can require multiple tests in sequence which can make the process of diagnosis long and inconvenient for patients. In the UK, there have been challenges providing enough testing for COPD and asthma, in part because the tests are challenging to provide in the community to everyone who needs one. The STARDUST study aims to test and develop new ways of diagnosing asthma and COPD that are quick, accurate and easy for patient and healthcare professionals to perform. People who have been referred for routine lung testing will breathe normally in and out into a handheld device called the N-Tidal Handset for 75 seconds. This device measures how the level of carbon dioxide (CO2) changes in the breath as people breath through it. The information gathered on the N-Tidal Handsets, called breath records or capnograms, will not be used to alter the diagnosis of any participants in the study. After the capnograms have been collected, the research team will test 'algorithms' that have been developed using artificial intelligence, to see if they can accurately identify the correct diagnosis. Information collected in the study will also be used to make improvements in these algorithms. If confirmed to be accurate, these algorithms could be used in clinical practice to help healthcare professionals make faster, more accessible and accurate diagnoses, especially in settings like GP clinics in the community where access to specialist tests may be limited.

Начало: 01.04.2026 Край: 19.05.2027 Възраст: 18–110 г.

United Kingdom Liverpool Heart and Chest Hospital NHS Foundation Trust NCT07253883

Предстои набиране

Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World Study

Atopic Dermatitis (AD)

Atopic dermatitis (AD) is a skin condition characterized by a rash and itching, resulting from skin inflammation. Ivarmacitinib is an approved medication for treating AD. This study assessed the efficacy and safety of switching to the JAK1 inhibitor ivarmacitinib over 16 weeks in patients with moderate-to-severe atopic dermatitis and inadequate response to IL-4Rα inhibitors under real-world conditions. It is expected that there will be no additional burden for participants in this trial.

Начало: 31.03.2026 Край: 31.07.2027 Възраст: 18–75 г.

Peking University People's Hospital NCT07550452

Предстои набиране Фаза 2

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma

Peripheral T-Cell Lymphoma (PTCL NOS) Nodal T-follicular Helper Cell Lymphoma Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative)

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of rare disorders that result from clonal proliferation of mature post-thymic lymphocytes. These T-cell neoplasms account for approximately 10-15% of all lymphomas. The most common subtype of PTCL is classified as "not otherwise specified" (NOS) which accounts for 30-40%. PTCLs have been treated similarly with CHOP (Cyclophosphamide, Hydroxydaunorubicin, Vincristine and Prednisone), often with etoposide (CHOEP), followed by high-dose therapy and autologous stem cell transplantation (ASCT) in first remission. However, \

Начало: 30.03.2026 Край: 30.12.2028 Възраст: от 65 г.

China Shanghai Jiao Tong University School of Medicine NCT07535762

1 … 194 195 196 197 198 … 240